Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review
type: CreativeWork
description: Background Osteosarcoma mostly occurs during the period of rapid bone growth in children and adolescents as high-grade osteosarcomas. Current treatment recommended for high-grade non-metastatic and metastatic and/or relapsed osteosarcoma involves neoadjuvant multiagent conventional chemotherapy, followed by surgical resection of macroscopically detected tumour and postoperative adjuvant chemotherapy. However, residual micrometastatic deposits that develop following surgery have shown resistance to postoperative/adjuvant chemotherapy. Therefore, there is a critical need for more effective and innovative therapeutic approaches such as immune stimulatory agents. The most extensively studied immune stimulatory agent in the treatment of osteosarcoma is mifamurtide. The aim of this systematic review was to identify and synthesise the evidence on the effectiveness of mifamurtide in addition to standard chemotherapy on survival outcomes. Objectives To present the best available evidence related to the treatment of high-grade non-metastatic and metastatic osteosarcoma with mifamurtide in addition to standard chemotherapy. Inclusion criteria Types of participants All populations of patients, regardless of age, gender or ethnicity with high-grade, resectable, non-metastatic and metastatic osteosarcoma based on histological diagnosis. Types of interventions and comparators This review focused on intravenous infusion of either of the pharmaceutical formulations of mifamurtide (MTP-PE or L-MTP-PE) in addition to standard chemotherapy, and the comparator was chemotherapy alone. Types of studies This review considered any experimental study design including randomised controlled trials, non-randomised trials and quasi-experimental studies. Types of outcomes The primary outcomes of interest were event-free survival, overall survival and recurrence of osteosarcoma. Secondary outcomes that were considered included health-related quality of life and any mifamurtide-related adverse even…
abstract: Background Osteosarcoma mostly occurs during the period of rapid bone growth in children and adolescents as high-grade osteosarcomas. Current treatment recommended for high-grade non-metastatic and metastatic and/or relapsed osteosarcoma involves neoadjuvant multiagent conventional chemotherapy, followed by surgical resection of macroscopically detected tumour and postoperative adjuvant chemotherapy. However, residual micrometastatic deposits that develop following surgery have shown resistance to postoperative/adjuvant chemotherapy. Therefore, there is a critical need for more effective and innovative therapeutic approaches such as immune stimulatory agents. The most extensively studied immune stimulatory agent in the treatment of osteosarcoma is mifamurtide. The aim of this systematic review was to identify and synthesise the evidence on the effectiveness of mifamurtide in addition to standard chemotherapy on survival outcomes. Objectives To present the best available evidence related to the treatment of high-grade non-metastatic and metastatic osteosarcoma with mifamurtide in addition to standard chemotherapy. Inclusion criteria Types of participants All populations of patients, regardless of age, gender or ethnicity with high-grade, resectable, non-metastatic and metastatic osteosarcoma based on histological diagnosis. Types of interventions and comparators This review focused on intravenous infusion of either of the pharmaceutical formulations of mifamurtide (MTP-PE or L-MTP-PE) in addition to standard chemotherapy, and the comparator was chemotherapy alone. Types of studies This review considered any experimental study design including randomised controlled trials, non-randomised trials and quasi-experimental studies. Types of outcomes The primary outcomes of interest were event-free survival, overall survival and recurrence of osteosarcoma. Secondary outcomes that were considered included health-related quality of life and any mifamurtide-related adverse even…
author: Jimmy, Rincy
keywords: osteosarcoma, osteogenic sarcoma, mifamurtide, muramyl tripeptide
date published: 2018
date modified: 2026-07-24T00:51:08Z
provider: University of Adelaide
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: University of Adelaide

PropertyValue
property ID: Handle
value: http://hdl.handle.net/2440/114432

PropertyValue
property ID: DOI
value: 10.25909/5b99c93d701d4